 The purpose of this study is to evaluate the use of quetiapine to diminish cue reactivity to a Virtual Reality environment for individuals with Social Phobia. The following primary and secondary outcome measures will be administered to subjects during each Virtual Reality exposure in treatment and non-treatment conditions. The outcome measures have demonstrated adequate reliability and validity in the detection of clinical change for individuals with social phobia in open label studies using quetiapine Schutters, van Megen, and Westenberg, 2005. The Personal Report of Confidence as a Speaker PRCS; Paul, 1966 will be utilized as the primary measure to establish individual diagnosis and severity level. Pertaub and Slater 2002 demonstrated the sensitivity of the PRCS in measuring anxiety responses to virtual audiences. A total score of 21 or greater on the PRCS will be required for study inclusion Carrigan and Levis, 1999. Carrigan and Lewis 1999 reported a mean score of 23.73 on the 30-item PRCS for individuals reporting fear of public speaking. Subjective units of distress ratings and measures of blood pressure and heart rate will be obtained within session in order to measure immediate changes in subjects cue reactivity to VRE stimuli. The outcome measures include: 